Alveo Technologies news

Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). Soistman is an accomplished business executive who has decades of experience driving profitable growt

Alveo Technologies, Inc. (Alveo) announced today that it has been named a winner of the $6M XPRIZE Rapid COVID Testing Competition for its be.well COVID-19 Test. The be.well™ platform provides individuals access to molecular testing and cloud-based analytics for rapid diagnosis and management of infectious diseases.   

The $6 million XPRIZE Rapid

Alveo Technologies, Inc. (Alveo) announced today that it has received its first regulatory approval with the CE (Conformité Européenne) Mark for its be.well COVID-19 Flex Test.  The be.well platform is a molecular test based on an isothermal nucleic acid amplification process, and has a real-time healthcare data application program to help accelerate time to COVID-19 treatment and surveillance. 

“Alveo is pleas

Alveo Technologies, today announced it has been awarded a grant to improve upon the performance and usability of its testing platform, and if successful, to advance the development and scale manufacturing of the company’s be.well™ COVID-19 test from the Bill & Melinda Gates Foundation. As the first of its kind platform, 

Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Professor Justin Stebbing M.D., Ph.D., has been appointed to its Scientific Advisory Board (SAB). In this role, Professor Ste

Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™

We are thrilled to announce today that in February 2020 Alveo Technologies was presented with a Food and Drug Branch License (FDB License) after an in-person inspection by a Food and Drug Investigator from the State of California Food and Drug Branch of the Food and Drug Administration. This license is critical to the success of our company as it is a requirement of the State of California in order to manufac

Our company is delighted to announce today, February 1, 2020, that Pooja Goel, Managing Director and Healthcare Practice Lead at Virgo Investment Group, LLC, is joining Alveo’s Scientific Advisory Board. Having held key operational roles responsible for new market and business opportunities as well as process and clinical improvements, Goel brings a deep bench of knowledge to Alveo.

“Alveo’s advanced diagnostics clear the path to more personalized medicine and better

We are pleased to announce that famed American Geneticist George Church will be joining Alveo’s Scientific Advisory Board. With extensive background in medical diagnostics, including founding application-based companies, George will bring valuable expertise to our Board as we continue to grow and democratize our healthcare system.

“At Alveo, we are focused on intercepting the spread of infectious diseases utilizing agile and dynamic technology that brings rapid diagnosis t